Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study

Figure 1 Mean hepatitis C virus (HCV)-RNA levels during the first 24 wk of treatment in patients with HCV genotype 1 infection receiving PEG-IFNα2a plus ribavirin (PR) or PEG-IFNα2a plus ketoprofen (PK) or PEG-IFNα2a plus ribavirin and ketoprofen (PRK).

Figure 2 Mean reduction from baseline in log₁₀ HCV-RNA levels in patients with HCV genotype 1 infection receiving PR or PK or PRK.

Figure 3 Mean percentage increase from baseline in STAT1 protein density in patients with HCV genotype 1 infection receiving PR or PK or PRK. Data are presented as the mean (± SD) percentage increase over basal activity in STAT1, assessed by densitometric analysis. ^aP < 0.05.

Figure 4 2’-5’-oligoadenylate synthetase (2’-5’OAS) induction in patients with HCV genotype 1 infection receiving PR or PK or PRK. Data are presented as the mean (± SD) fold increase over basal activity in 2’-5’OAS mRNA levels, assessed by RTQ-PCR. ^aP < 0.05.